Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models

Overview of attention for article published in Molecular Cancer Therapeutics, March 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

policy: 1 policy source

patent: 57 patents

Citations

dimensions_citation: 285 Dimensions

Readers on

mendeley: 194 Mendeley

Summary Policy documents Patents Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Iclusig for Chronic Myeloid Leukemia/ Acute Lymphoblastic Leukemia – Details

Cited by Canadian Agency for Drugs and Technologies in Health on 01 Jun 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.